---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-026106"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:37:40.568011+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Galectin Therapeutics Q1 net loss $0.19/share; cash $23.6M; NAVIGATE trial on track for Q4 2024 interim data

## Summary
- Net loss $11.5M ($0.19 per share) for Q1 2024, unchanged from Q1 2023.
- Cash and equivalents $23.6M; additional $20M available from chairman's credit lines (two $10M facilities).
- Fifth DSMB recommended continuation of NAVIGATE Phase 2b/3 trial of belapectin in MASH cirrhosis without modifications.
- Interim top-line data from Phase 2b portion expected late Q4 2024.
- Appointed Khurram Jamil, M.D. as Vice President of Clinical Development.

## SEC filing metadata
- accession: 0001140361-24-026106
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036124026106/0001140361-24-026106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036124026106/ef20028923_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-026106
- JSON: https://secwatch.observer/filing/0001140361-24-026106.json
- Plain text: https://secwatch.observer/filing/0001140361-24-026106.txt

## Key facts
- Earnings Releases
  GALECTIN THERAPEUTICS INC reported the quarter ended March 31, 2024 results: net income net loss of $11.5 million, EPS ($0.19) per share.
  - Period: the quarter ended March 31, 2024
  - Net income: net loss of $11.5 million
  - EPS: ($0.19) per share
  - Result: reported results
  source text: For the quarter ended quarter ended March 31, 2024, the Company reported a net loss applicable to common stockholders of $11.5 million, or ($0.19) per share, compared to a net loss applicable to common stockholders of $11.5 million, or ($0.19) per share for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133416/000114036124026106/0001140361-24-026106-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.